Open AccessInfluenza vaccination for immunocompromised patients: summary of a systematic review and meta‐analysis
Author(s) -
Beck Charles R,
McKenzie Bruce C,
Hashim Ahmed B,
Harris Rebecca C,
Zanuzdana Arina,
Agboado Gabriel,
Orton Elizabeth,
BéchardEvans Laura,
Morgan Gemma,
Stevenson Charlotte,
Weston Rachel,
Mukaigawara Mitsuru,
Enstone Joanne,
Augustine Glenda,
Butt Mobasher,
Kim Sophie,
Puleston Richard,
Dabke Girija,
Howard Robert,
O'Boyle Julie,
O'Brien Mary,
Ahyow Lauren,
Denness Helene,
Farmer Siobhan,
Figureroa Jose,
Fisher Paul,
Greaves Felix,
Haroon Munib,
Haroon Sophie,
Hird Caroline,
Isba Rachel,
Ishola David A,
Kerac Marko,
Parish Vivienne,
Roberts Jonathan,
Rosser Julia,
Theaker Sarah,
Wallace Dean,
Wigglesworth Neil,
Lingard Liz,
Vinogradova Yana,
Horiuchi Hiroshi,
Peñalver Javier,
NguyenVanTam Jonathan S
Publication year - 2013
Publication title -
influenza and other respiratory viruses
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.743
H-Index - 57
eISSN - 1750-2659
pISSN - 1750-2640
DOI - 10.1111/irv.12084
Subject(s) - meta analysis , medicine , vaccination , intensive care medicine , immunology , virology
Vaccination of immunocompromised patients is recommended in many national guidelines to protect against severe or complicated influenza infection. However, due to uncertainties over the evidence base, implementation is frequently patchy and dependent on individual clinical discretion. We conducted a systematic review and meta‐analysis to assess the evidence for influenza vaccination in this patient group. Healthcare databases and grey literature were searched and screened for eligibility. Data extraction and assessments of risk of bias were undertaken in duplicate, and results were synthesised narratively and using meta‐analysis where possible. Our data show that whilst the serological response following vaccination of immunocompromised patients is less vigorous than in healthy controls, clinical protection is still meaningful, with only mild variation in adverse events between aetiological groups. Although we encountered significant clinical and statistical heterogeneity in many of our meta‐analyses, we advocate that immunocompromised patients should be targeted for influenza vaccination.